Telomerase and the benefits of healthy living.

www.thelancet.com/oncology Vol 9 November 2008 1023 diabetes, hyperlipidaemia, or obesity, whether large, comprehensive randomised trials addressing the use of such interventions in obese patients with prostate cancer are even needed could be questioned. Most men with prostate cancer die of causes other than prostate cancer, and therefore oncologists should already be recommending lifestyle changes to all patients, especially to those who are overweight or diabetic. A message from oncologists advocating healthier lifestyles might improve our patients’ cardiovascular and metabolic clinical profi les, but might also modify the tumour-cell medium for an improved patient outcome.